TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07607678: A First-in-human Phase I, Open-label, Multicentre, Dose Escalation Trial of BI 3819026 in Combination With Ezabenlimab in Patients With Unresectable Advanced or Metastatic Solid Cancers to Determine the Maximum Tolerated

Sponsor: Boehringer Ingelheim · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 60 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$6,597,360

Rescue Site Savings

+$4,366,824

Unlock Full NCT07607678 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07607678 Rescue Dossier →